[
  {
    "account_name": "AstraZeneca",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 22.836927038259464,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | trial_collaborator: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | trial_collaborator: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
    "best_fit_trial_title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04257578",
    "best_urgency_trial_title": "Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07201558",
    "sec": {
      "recent_total": 5,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": "2026-02-10T00:00:00+00:00",
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AstraZeneca",
    "total_score": 22.836927038259464,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07201558",
      "https://clinicaltrials.gov/study/NCT04594642",
      "https://clinicaltrials.gov/study/NCT07215585",
      "https://clinicaltrials.gov/study/NCT07295847",
      "https://clinicaltrials.gov/study/NCT06542250",
      "https://www.sec.gov/Archives/edgar/data/901832/000165495426001073/a3234s.htm",
      "https://clinicaltrials.gov/study/NCT06897930",
      "https://clinicaltrials.gov/study/NCT07391657"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-17T00:00:00+00:00",
      "most_recent_other_matched": null
    }
  },
  {
    "account_name": "Pfizer",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.66750714274709,
    "fit_reason": "molecule match: elranatamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guide | trial_collaborator: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | trial_collaborator: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra",
    "best_fit_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "best_urgency_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Pfizer",
    "total_score": 20.66750714274709,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06215118",
      "https://clinicaltrials.gov/study/NCT05748171",
      "https://clinicaltrials.gov/study/NCT06152575",
      "https://clinicaltrials.gov/study/NCT05623020",
      "https://clinicaltrials.gov/study/NCT05020236",
      "https://clinicaltrials.gov/study/NCT06057402",
      "https://clinicaltrials.gov/study/NCT05675449",
      "https://clinicaltrials.gov/study/NCT06974786"
    ],
    "score_details": {
      "trial_count": 14,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-05T00:00:00+00:00",
      "most_recent_other_matched": null
    }
  },
  {
    "account_name": "GSK",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 4.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "GSK",
    "total_score": 4.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": null,
      "most_recent_other_matched": null
    }
  }
]